SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Menard S, Pierotti MA, Testori A. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49: 449.
  • 2
    Ciocca DR, Fujimura FK, Tandon AK. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1,103 breast cancer. J Nat Cancer Inst 1992;84: 127982.
  • 3
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 17782.
  • 4
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244: 70712.
  • 5
    Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53: 496070.
  • 6
    Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA. Correlation between c-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51: 55667.
  • 7
    Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7: 11208.
  • 8
    Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49: 6505.
  • 9
    Uehara T, Kaneko Y, Kanda N, Yamamoto T, Higashi Y, Nomoto C, Izumo T, Takayama S, Sakurai M. C-2 and c-1 (ear-1) gene amplification and c-erb-2 protein in Japanese breast cancers: their relationship to the histology and other disease parameters. Jpn J Cancer Res 1990;81: 62024.
  • 10
    Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P. Specific-expression of the pS2 gene in subclasses of breast cancer in comparison with expression of the estrogen and progesterone receptor and the oncogene ERBB2. Proc Natl Acad Sci USA 1987;84: 92437.
  • 11
    Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL, Altman DG. C-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63: 4348.
  • 12
    Van de Vijver MP, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in Stage II breast cancer. N Engl J Med 1988;319: 123945.
  • 13
    Gullick WJ, Love SB, Wright C, Barnes DH, Gusterson B, Harris AL, Altman DG. CerbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63: 4348.
  • 14
    Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A, Gion M. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 1997;17: 12458.
  • 15
    Koscielny S, Terrier P, Daver A, Wafflart J, Goussard J, Ricolleau G, Delvincourt C, Delarue JC. Quantitative determination of c-erbB-2 in human breast tumors: potential prognostic significance of low values. Eur J Cancer 1998;34: 47681.
  • 16
    Carney WP, Harmer PJ, Petit D, Retos C, Greene R, Zabrecky JR, et al. Detection and quantitation of the human Neu oncoprotein. J Tumor Marker Oncol 1991;6: 5372.
  • 17
    Koscielny S, Terrier P, Spielmann M, Delarue JC. Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst 1998;90: 712.
  • 18
    McKenzie SJ, Marks PJ, Lam T, Morgan J, Panicali DL, Trimpe K, Carney WP. Generation and characterization of monoclonal antibodies specific for the human Neu oncogene product, p185. Oncogene 1989;4: 5438.
  • 19
    Valerón PF. Metodología para el estudio del oncogén HER-2/neu en cáncer de mama: correlación con paráemetros clínicos y con receptores de estrógenos y progesterona. Universidad de Las Palmas de GC: Thesis Doctoral; 1994.
  • 20
    Valerón PF, Chirino R, Fernández L, Torres S, Navarro D, Aguiar J, Cabrera JJ, Diaz-Chico BN, Diaz-Chico JC. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int J Cancer 1996; 65: 12933.
  • 21
    Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51: 9448.
  • 22
    Foekens JA, van Putten W, Portengen H, de Koning H, Thirion B, Alexieva-Figussch J, Klijn JG. Prognostic value of pS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 1993;11: 899908.
  • 23
    Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 1993;24: 21926.
  • 24
    Valagusa P, Bonadonna G, Veronesi U. Pattern of relapse and survival following radical mastectomy. Cancer 1978;41: 11708.
  • 25
    Singletary SE. Management of the axilla in early stage breast cancer. In: ASCO. Educational book. Los Angeles: 34th Annual Meeting; 1998. 132141.
  • 26
    Ravdin PM. Prognostic factors in breast cancer. In: BonadonnaG. HortobagyiG, GianniAM, eds. A clinical guide to therapy. London: Martin Dunitz, Ltd.; 1997. 3563.
  • 27
    Henson DE, Ries L, Carriaga M. Relationship among outcome, stage of disease and histologic grade in 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68: 21429.
  • 28
    Fisher B, Slack NH, Biass ID. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969;24: 107180.
  • 29
    Carter CL, Allen C, Henson D. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63: 1817.
  • 30
    Van Lancker M, Goor C, Sacre R, Lamote J, Vanbelle S, Decoene N, Roelstraete A, Storme G. Patterns of axillary lymph nodes metastasis in breast cancer. Am J Clin Oncol 1995;18: 26772.
  • 31
    Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987;5: 77382.
  • 32
    Koscienly S, Le M, Tubiana M. The natural history of human breast cancer: the relationship between involvement of axillary lymph nodes and the initiation of distant metastases. Br J Cancer 1989;59: 77582.
  • 33
    Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73: 235965.
  • 34
    Quënel N, Wafflart J, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35: 28391.
  • 35
    Anbazhagan R, Gelber RD, Bettelheim R, Goldrirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 1991;2: 4753.
  • 36
    Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74: 295663.
  • 37
    Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989;49: 714752.
  • 38
    Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50: 43327.
  • 39
    Eissa S, Khalifa A, El-Gharib A, Salah N, Mohamed MK. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 1997;17: 30918.
  • 40
    Gullick WJ. The role of the epidermal growth factor receptor and the c-2 protein in breast cancer. Int J Cancer Suppl 1990;5: 5561.
  • 41
    Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, Gullick WK, Elston CW, Blamey RW. C-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63: 43943.
  • 42
    Nugent A, McDermott E, Duffy K, O'Higgins N, Fennelly JJ, Duffy MJ. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer. Clin Chem 1992;38: 14714.
  • 43
    Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M. C-erbB-2 and ras expression levels in breast cancer are correlated and show a cooperative association with unfavorable clinical outcome. Int J Cancer 1991;47: 8338.
  • 44
    Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10: 104956.
  • 45
    García I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E. Genetic alterations of c-myc, c-2, and c-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 1989;49: 66759.
  • 46
    Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990;114: 1603.